Clinical Trials Directory

Trials / Conditions / Relapsed Adult AML

Relapsed Adult AML

21 registered clinical trials studyying Relapsed Adult AML — 7 currently recruiting.

StatusTrialSponsorPhase
RecruitingStudy Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19
NCT06649227
University Hospital, LillePhase 1
RecruitingStudy of Oral PCLX-001 in R/R Acute Myeloid Leukemia
NCT06613217
Pacylex PharmaceuticalsPhase 1
WithdrawnTislelizumab with Azacitidine in the Treatment of R/R AML
NCT06586099
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1 / Phase 2
WithdrawnVenetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid
NCT06007911
Medical College of WisconsinPhase 1
RecruitingCLL-1 CAR-NK Cells for Relapsed/Refractory AML
NCT06307054
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicinePhase 1
RecruitingStudy Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilter
NCT06022003
French Innovative Leukemia OrganisationPhase 2
UnknownPlerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
NCT06141304
The First Hospital of Jilin UniversityPhase 2
WithdrawnVenetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
NCT03932318
Actinium PharmaceuticalsPhase 1 / Phase 2
RecruitingSpecialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
NCT05237258
Massachusetts General HospitalN/A
RecruitingVenetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
NCT05305859
The First Affiliated Hospital of Xiamen UniversityPhase 2
Active Not RecruitingNew Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT05029141
The First Affiliated Hospital of Soochow UniversityPhase 2
CompletedA Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloi
NCT05193448
French Innovative Leukemia Organisation—
UnknownPD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AM
NCT04722952
The First Affiliated Hospital of Soochow UniversityPhase 3
CompletedDose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in P
NCT04139434
Newave Pharmaceutical IncPhase 1
UnknownTrial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
NCT04330820
Technische Universität DresdenPhase 1 / Phase 2
TerminatedNatural Killer Cell (CYNK-001) Infusions in Adults with AML
NCT04310592
Celularity IncorporatedPhase 1
UnknownVenetoclax and Lintuzumab-Ac225 in AML Patients
NCT03867682
Actinium PharmaceuticalsPhase 1 / Phase 2
CompletedPracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03848754
Medical College of WisconsinPhase 1
RecruitingClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43
NCT03850574
Aptose Biosciences Inc.Phase 1 / Phase 2
UnknownAntiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Follow
NCT03091933
Ciusss de L'Est de l'Île de MontréalPhase 1 / Phase 2
Approved For MarketingIvosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
NCT03245424
Agios Pharmaceuticals, Inc.—